BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38245379)

  • 1. Impact of tissue-agnostic approvals on management of primary brain tumors.
    Ahluwalia MS; Khosla AA; Ozair A; Gouda MA; Subbiah V
    Trends Cancer; 2024 Mar; 10(3):256-274. PubMed ID: 38245379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of tissue-agnostic approvals for patients with sarcoma.
    Pestana RC; Beal JR; Parkes A; Hamerschlak N; Subbiah V
    Trends Cancer; 2022 Feb; 8(2):135-144. PubMed ID: 34887213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies.
    Bhamidipati D; Subbiah V
    Trends Cancer; 2023 Mar; 9(3):237-249. PubMed ID: 36494311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current Status and Challenges in Tumor Agnostic Treatment].
    Komine K
    Gan To Kagaku Ryoho; 2023 Jun; 50(6):657-661. PubMed ID: 37317595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
    Iannantuono GM; Torino F; Rosenfeld R; Guerriero S; Carlucci M; Sganga S; Capotondi B; Riondino S; Roselli M
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications.
    Gouda MA; Nelson BE; Buschhorn L; Wahida A; Subbiah V
    Clin Cancer Res; 2023 Aug; 29(15):2753-2760. PubMed ID: 37061987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group.
    Vranic S; Basu GD; Hall DW; Gatalica Z
    Acta Med Acad; 2022 Dec; 51(3):217-231. PubMed ID: 36799315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of pembrolizumab among older adults with cancer in the United States, before and after FDA approval of its tumor-agnostic indication.
    Hong YD; Enewold L; Halpern MT; Zeruto C; Mariotto AB
    Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5745. PubMed ID: 38156547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics.
    Tateo V; Marchese PV; Mollica V; Massari F; Kurzrock R; Adashek JJ
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of histology-agnostic treatments in metastatic colorectal cancer.
    Sartore-Bianchi A; Agostara AG; Patelli G; Mauri G; Pizzutilo EG; Siena S
    Dig Liver Dis; 2022 Oct; 54(10):1291-1303. PubMed ID: 35701319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the 'NSCLC' of GI Oncology?
    Gupta A; Kurzrock R; Adashek JJ
    Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. If it's a target, it's a pan-cancer target: Tissue is not the issue.
    Adashek JJ; Kato S; Sicklick JK; Lippman SM; Kurzrock R
    Cancer Treat Rev; 2024 Apr; 125():102721. PubMed ID: 38522181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection.
    Capper D; Reifenberger G; French PJ; Schweizer L; Weller M; Touat M; Niclou SP; Euskirchen P; Haberler C; Hegi ME; Brandner S; Le Rhun E; Rudà R; Sanson M; Tabatabai G; Sahm F; Wen PY; Wesseling P; Preusser M; van den Bent MJ
    Neuro Oncol; 2023 May; 25(5):813-826. PubMed ID: 36632791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape.
    Glaire MA; Ryan NA; Ijsselsteijn ME; Kedzierska K; Obolenski S; Ali R; Crosbie EJ; Bosse T; de Miranda NF; Church DN
    J Pathol; 2022 Jul; 257(3):340-351. PubMed ID: 35262923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision medicine becomes reality-tumor type-agnostic therapy.
    Yan L; Zhang W
    Cancer Commun (Lond); 2018 Mar; 38(1):6. PubMed ID: 29764494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue-Agnostic Drug Development: A New Path to Drug Approval.
    Thein KZ; Lemery SJ; Kummar S
    Cancer Discov; 2021 Sep; 11(9):2139-2144. PubMed ID: 34479971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Histology-agnostic tumor treatment - a farewell to tumor entities?].
    Kerle I; Heining C
    Dtsch Med Wochenschr; 2023 Sep; 148(18):1174-1181. PubMed ID: 37657455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS.
    Wang J; Yi Y; Xiao Y; Dong L; Liang L; Teng L; Ying JM; Lu T; Liu Y; Guan Y; Pang J; Zhou L; Lu J; Zhang Z; Liu X; Liang X; Zeng X; Yi X; Zhou W; Xia X; Yang L; Zhang J; Kopetz S; Futreal PA; Wu H; Liang Z
    Mod Pathol; 2019 Jul; 32(7):1053-1064. PubMed ID: 30723297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic Alterations of NTRK, POLE, ERBB2, and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer.
    Guo Y; Guo XL; Wang S; Chen X; Shi J; Wang J; Wang K; Klempner SJ; Wang W; Xiao M
    Oncologist; 2020 Nov; 25(11):e1671-e1680. PubMed ID: 32627883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic and predictive impact of
    Park R; Lopes L; Lee S; Riano I; Saeed A
    Future Oncol; 2021 Nov; 17(31):4221-4231. PubMed ID: 34323124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.